NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
Karyopharm Therapeutics Inc
Duke University
Case Comprehensive Cancer Center
Methodist Healthcare